1-3 of 3
Larry J Suva, PhD
Close
Sort by
Journal Articles

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Antonio Branca, MD, Amy Buros, PhD, Donghoon Yoon, PhD, Larry J Suva, PhD, Niels Weinhold, PhD, Leo Rasche, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Cerisse Harcourt, APRN, OCN, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD, Maurizio Zangari, MD
Journal: Blood
Blood (2016) 128 (22): 4516.
https://doi.org/10.1182/blood.V128.22.4516.4516
Published: 2016
Journal Articles

Heparanase Promotes Myeloma Metastasis By Inducing EMT-like Features in Both Myeloma Cells and Endothelial Cells

Qianying Pan, MD, Patrick D Rowan, BS, Racquel Innis-Shelton, MD, Timothy N Trotter, BS, Mei Li, PhD, Deniz Peker, MD, Larry J Suva, PhD, Yang Yang, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2025.
https://doi.org/10.1182/blood.V124.21.2025.2025
Published: 2014
Journal Articles

Heparanase Promotes the Spontaneous Metastasis of Myeloma Cells to Bone.

Yang Yang, MD, PhD, Veronica MacLeod, MS, Manali Bendre, PhD, Yan Huang, Allison M. Theus, BA, Hua-Quan Miao, PhD, Paul Kussie, PhD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Larry J. Suva, PhD, Thomas Kelly, PhD, Ralph D. Sanderson, PhD
Journal: Blood
Blood (2004) 104 (11): 635.
https://doi.org/10.1182/blood.V104.11.635.635
Published: 2004